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Summary 
Fresh leukemic cells from patients with adult T  cell leukemia (ATL) and some ATL-derived T 
cell hnes show adhesion to human umbilical vein endothelial cells  (HUVECs) mainly through 
E-selectin, but a proportion of this binding remains unaffected by the addition of combinations 
of antibodies against known adhesion molecules. By immunizing mice with one of such cell 
hnes, we estabhshed monoclonal antibodies (mAbs), termed 131  and 315, that recognize a sin- 
gle cell surface antigen  (Ag)  and inhibit the remaining pathway of the adhesion.  These mAbs 
did not react with normal resting peripheral blood mononuclear cells  (PBMC) or most of the 
cell lines tested except for two other human T  cell leukemia virus type I (HTLV-I)-infected T 
cell hnes.  After stimulation with phytohemagglutinin  (PHA),  PBMC  expressed Ag  131/315 
transiently, indicating that these mAbs define a T  cell activation Ag. Western blotting and im- 
munoprecipitation revealed that Ag 131/315 has an apparent molecular mass of 50 kD. Expres- 
sion cloning was done by transient expression in COS-7 cells and immunological selection to 
isolate a cDNA clone encoding Ag 131/315. Sequence analysis of the cDNA indicated that it is 
identical to human OX40, a member of the tumor necrosis factor/nerve growth factor recep- 
tor family. We then found that gp34,  the hgand of OX40,  was expressed on HUVECs and 
other types of vascular endothehal cells.  Furthermore, it was shown that the adhesion ofCD4 + 
cells ofPHA-stimulated PBMC to unstimulated HUVECs was considerably inhibited by either 
131  or 315.  Finally, OX40  transfectants of Kit 225,  a human interleukin 2-dependent T  cell 
line, were bound specifically to gp34 transfectants of MMCE,  a mouse epithelial cell hne, and 
this binding was blocked by either 315 or 5A8, an anti-gp34 mAb. These results indicate that 
the OX40/gp34 system directly mediates adhesion of activated T  cells or OX40+-transformed 
T  cells to vascular endothehal cells. 
T 
he trafficking and localization  of circulating lympho- 
cytes are regulated by interaction between several pairs 
of adhesion molecules expressed on lymphocytes and vas- 
cular endothehal cells. Tissue specificity of lymphocyte hom- 
ing has been explained by selective expression of certain sets 
of adhesion molecules on subsets oflymphocytes as well as 
tissue-specific high endothehal venules. In mice, the mole- 
cules involved in each step of cell adhesion, namely, cell at- 
tachment, rolling, and adhesion (sticking),  have been identi- 
fied in different organs and tissues  under ex vivo conditions 
(1-8).  In  humans,  where  umbilical  vein  endothehal  cells 
(HUVECs) 1 are commonly used for in vitro experiments, 
at least three combinations of adhesion molecules are known 
to  be important:  LFA-1/intercellular  cell  adhesion  mole- 
cules  1 and 2  (ICAM-1,-2); very late antigen 4  (VLA-4)/ 
vascular cell adhesion molecule  1  (VCAM-1),  and several 
IAbbreviations used in this paper: ATL, adult T cell leukemia; HAEC, hu- 
man aortic endothehal cell; HDMEC, human dermal microvascular  en- 
dothehal cell; HUVEC, human umbilical  vein endothelial cell; ICAM-1, 
intercellular adhesion molecule 1; NGF, nerve growth factor; VCAM-1, 
vascular cell adhesion molecule 1; VLA-4, very  late antigen 4. 
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selectins  (9-17).  It is also indicated  that  CD6,  CD44,  and 
some  other  molecules  can  contribute  to  cell  adhesion  in 
certain circumstances (18-22). 
Although not yet confirmed, there have been reports sug- 
gesting the  presence  of unknown  adhesion  pathways  (23, 
24). Our group previously reported that fresh leukemic cells 
from patients with adult T  cell leukemia  (ATL), which of- 
ten manifests infiltration of malignant cells into a variety of 
organs such as skin, lung, and intestine,  adhere to HUVECs 
predominantly through E-selectin and VCAM-1 expressed 
on endothelial cells (25-28). Data were presented implying 
that some part of this adhesion is likely to be mediated by 
unknown pathway(s) since it was only partially blocked by 
combinations  of mAbs against  LFA-1, VLA-4, E-selectin, 
and other known adhesion molecules. Further characteriza- 
tion was hindered because of limited availability and varia- 
tion of fresh leukemic cell samples.  However, we have re- 
cently found that  among HTLV-I-infected human T  cell 
lines, ATL-43T (Maeda, M., unpublished results),  a human 
double  negative  T  cell  line  derived  from  a  patient  with 
ATL, maintains  high levels  of unknown  adhesion  activity 
to  HUVECs.  It  adheres  considerably  to  unstimulated 
HUVECs,  which  cannot  be  blocked  by combinations  of 
mAbs against known adhesion molecules. 
Recent  evidence has disclosed that the phenomenon of 
cell adhesion is comprised of complicated sequential events 
involving ligand receptor recognition  and subsequent  cel- 
lular  activation.  Several  cytokines,  as  well  as  membrane- 
bound costimulatory molecules,  augment cell adhesion by 
upregulating the expression or bindability  of certain adhe- 
sion molecules (29, 30).  It is now widely accepted that not 
only cytokines but also adhesion  molecules, upon binding 
to their ligands,  give rise  to activation signals that lead to 
the next step of cell adhesion (31-37).  Furthermore,  some 
cytokines of membrane-bound  form have been shown to 
transmit signals into the cell just like cytokine receptors or 
costimulatory molecules (38, 39). These findings as a whole 
have brought about the situation where the distinction be- 
tween the adhesion molecule and the costimulatory mole- 
cule or between  the ligand and the  receptor is not always 
self-evident.  The  next  remaining  question  is whether  the 
binding of any of the membrane-bound cytokines to their 
receptors  or  costimulatory  molecules  to  their  ligands  di- 
rectly mediates cell adhesion. Although there have been no 
definitive reports so far concerning this issue, we think that 
it  is  theoretically  possible  and  deserves  serious  consider- 
ation. 
In the present study, we developed mAbs against a cell sur- 
face Ag on ATL-43T that can inhibit its binding to HUVECs. 
We characterized these mAbs and cloned a cDNA encoding 
the antigen molecule recognized by these mAbs, which re- 
vealed  that  it  is  identical  to  the  human  counterpart  of rat 
OX40,  a  type I  transmembrane  protein  of the  TNF/nerve 
growth  factor  (NGF)  receptor  family  (40,  41).  Recently, 
the  ligand  for  OX40  has  been  identified  as  gp34,  which 
was initially  reported  as  an Ag expressed preferentially  on 
HTLV-I-infected  T  cell  lines  (42-46).  Here  we  present 
evidence that the OX40/gp34 receptor ligand system, which 
has been described as a pair of TNF receptor/TNF  family 
molecules with costimulatory function, directly mediates the 
binding of activated T  cells to HUVECs. 
Materials and Methods 
Cells and Culture Conditions.  IMDM  medium  (GIBCO  BRL, 
Gaithersburg,  MD) supplemented with 10% heat-inactivated FCS 
(Summit Biotechnology, Ft.  Collins,  CO)  and 30 t~g/ml tobra- 
mycin  (Shionogi  Pharmaceutical  Co.,  Osaka,  Japan)  was  used 
throughout this study unless otherwise stated. ATL-43T is an IL-2- 
dependent HTLV-I-infected human T cell line with a phenotype 
of CD3 +,  CD4-,  CD8-  established  from an ATL patient with 
intestinal  lymphoid involvement. Kit 225 is an IL-2-dependent 
human T  cell line  established  in  our laboratory from a patient 
with T  cell-type chronic lymphocytic leukemia (47). These cell 
lines were maintained in medium with 0.5 nM recombinant IL-2 
(kindly  provided by Shionogi Pharmaceutical Co). PBMC were 
isolated  from heparinized venous blood from normal donors by 
Ficoll-Paque  density  gradient  centrifugation.  PBMC  were  used 
freshly or after culture with 0.1 /~g/ml PHA (Murex Diagnostics 
Limited, Dartford, UK) for 3 d (PHA blasts). CD4 + PHA blasts 
were  prepared  by  negative  selection  using  immunomagnetic 
beads  (Dynabeads |  M-450; Dynal, Oslo, Norway) after incuba- 
tion with anti-CD8, anti-CD11b, anti-CD14, anti-CD16, and anti- 
CD20 mAbs.  HUVECs were  isolated  by collagenase  digestion 
according to the procedure ofJaffe et al.  (48). In brief,  umbilical 
cords obtained at normal deliveries  were washed with 70% etha- 
nol. The umbilical  veins were rinsed  with PBS and treated with 
0.1%  collagenase/PBS for 30 min at  room temperature.  Subse- 
quently, the collagenase  suspension  was harvested  and HUVECs 
were  obtained  by  centrifugation.  The  pelleted  cells were  sus- 
pended in M199 medium (GIBCO BRL) containing 15% FCS 
and  were  incubated  in  a  gelatin-coated  flask (Coming  Glass 
Works, Coming, NY). After incubation for 6 h at 37~  the en- 
dothelial  cells were washed and cultured in M199 medium sup- 
plemented with  15% FCS,  90  I~g/ml porcine intestinal  heparin 
(Sigma Chemical Co., St. Louis, MO), 30 Ixg/ml endothelial  cell 
growth supplement (Collaborative  Research, Inc., Bedford, MA), 
and  antibiotics.  HUVEC  monolayers were  then  maintained  in 
M199 medium containing the same additives in the second through 
the fourth passages and were used in the subsequent  assays. The 
endothelial  nature of the cells was confirmed by examining their 
morphological confluence and by detecting the expression  ofvon 
Willebrand factor using an immunofluorescence assay. Weak ex- 
pression  oflCAM-1 and no expression  of VCAM-1 and E-selec- 
tin on the resting HUVECs were demonstrated by flow cytomet- 
ric analysis, whereas the induction of marked expression  of these 
three molecules was noted after activation with 10 ng/ml of IL-113 
(kindly provided by Otsuka Pharmaceutical Co., Tokyo, Japan). 
Human aortic  endothelial cells (HAECs) and human dermal mi- 
crovascular  endothelial  cells derived from the  neonatal foreskin 
(HDMECs) were purchased from Kurabo (Osaka, Japan)  and cul- 
tured as described  above. 
mAbs.  mAbs were produced as described  elsewhere  (49). In 
brief,  spleen  cells from female  BALB/c mice  immunized  with 
ATL-43T cells were  fused  with  PAl  mouse  myeloma cells by 
polyethylene glycol (Sigma Chemical Co.) and subjected to selec- 
tion in HAT medium (Sigma Chemical Co.). Hybridoma super- 
natants were screened based on difference  in reactivity  with orig- 
inal ATL-43T and one of  its sublines that had lost adhesion activity 
to HUVECs after a long-term in vitro culture. The selected  su- 
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of  ATL-43T cells to HUVECs. Two independent mAhs, 131 and 
315, were found to satisfy these criteria, mAbs 131  and 315 were 
typed as IgG1 and IgG2a, respectively, using a mouse Ig typing 
kit (Sigma Chemical Co.) and purified from ascitic fluids using a 
mouse IgG purification kit (Amersham, Tokyo, Japan).  TS1/18 
(anti-CD18, the [3 chain of LFA-1), W6/32  (anti-MHC class I, 
control IgG1), Lym-1  (anti-CD20), OKM-1  (anti-CD11b), and 
OKT8  (anti-CD8)  were  also  purified from ascitic fluids of the 
hybridomas obtained from the American Type Culture Collec- 
tion (Rockville, MD). HP2/1 (anti-CD49d, the ~x chain of  VLA-4) 
was purchased from Immunotech S.A.  (Marseille, France). 7A9 
(anti-E-selectin) was kindly provided by Dr. W. Newman  (Ot- 
suka America Pharmaceutical Inc., Rockville, MD).  3G8  (anti- 
CD16) was a kind gift of Dr. J.C. Unkeless (Mount Sinai Medical 
Center,  New  York).  T(.[IR14  (anti-CD14)  was  purchased from 
DAKO (Glostmp, Denmark). Anti-gp34 mAbs, 5A8, 8F4, TAG34, 
and TARM34 were described elsewhere (44-46). 
Immunofluorescence Staining and Cytometric  Analysis.  Cells were 
stained by direct or indirect immunofluorescence and analyzed 
using a FACScan  |  (Becton Dickinson Immunocytometry Systems, 
San Jose, CA) as described previously (50). 
Cell Adhesion Assay.  HUVECs were plated onto gelatin-coated 
96-well plates and cultured until confluence with or without prior 
exposure to 10 ng/ml of IL-I[~ (Otsuka Pharmaceutical Co.) for 
4 h  at 37~  The cells were then rinsed twice with IMDM sup- 
plemented with 10% FCS. 10  s 5~Cr-labeled T  cells in a final vol- 
ume of 60 Dt were added to each well of HUVECs. After being 
left for 15 min at 37~  the HUVECs were washed gently four 
times with prewarmed IMDM/10%  FCS medium, and the re- 
maining adherent cells were lysed with 2% NP-40 in PBS. One 
half of this volume was counted in a Top Count (Packard Instru- 
ment Co., Inc., Meriden, CT).  Percent adhesion was calculated 
as the percentage of the count of remaining adherent cells to the 
count of input cells lysed with 2% NP-40 in PBS. To examine the 
effect of various mAbs on the binding ofT cells to IL-l-stimulated 
or  unstimulated  HUVECs,  SlCr-labeled T  cells  and  HUVECs 
were incubated separately with supernatants of hybridomas or a 
saturating concentration  (final concentration,  10  p,g/ml)  of each 
mAb for 10 nfin at room temperature after incubation with 5 p,g/ml 
human lgGs to block the nonspecific binding to Fc receptors. T 
cells were then added to the wells of HUVECs. All experiments 
were performed in triplicate. 
Western Blotting.  Western blotting was done as described (49). 
Cell lysates  from  5  ￿  106  cells were  mixed with  SDS  sample 
buffer, boiled for 5 rain, and electrophoresed through a 7.5-10% 
polyacrylamide gel. Samples were  electrotransferred onto sheets 
of Immobilon-P (polyvinylidene fluoride) (Millipore Corp., Bed- 
ford,  MA)  membranes.  The  membranes  were  incubated serially 
with blocking buffer and  with  diluted mAb solutions, washed, 
and then incubated with rabbit peroxidase-conjugated anti-mouse 
IgG (American Qualex, La Mirada, CA). After washing, the bind- 
ing of mAb was visualized by the  enhanced chemiluminescence 
detection kit (ECL; Amersham). 
Construction ofcDNA Libraries.  Poly(A)  + RNA was  prepared 
from 10  s ATL-43T cells using a Fast-Track mRNA isolation kit (In- 
vitrogen, San Diego, CA). Ohgo dT- and random hexamer-primed 
cDNAs were separately synthesized from 2  p~g poly(A)  + RNA 
and BstXI adaptors (Invitrogen) were added to each end. cDNA 
larger than  1 kb was selected by agarose gel electrophoresis and 
inserted into  the BstXI sites of the  expression vector pME18S 
(kindly provided by Dr. K. Maruyama, Tokyo Medical and Den- 
tal University, School of Medicine, Tokyo, Japan)  (51).  cDNA 
was transforlned into DH10B competent cells (GIBCO BR_L) by 
electroporation.  The  oligo  dT-primed  and  random  hexamer- 
primed cDNA libraries consisted of 8 ￿  105 and 1.2  ￿  106 inde- 
pendent clones, respectively. 
Expression Cloning.  Expression cloning was done according to 
the method described by B. Seed and co-workers (52-54) except 
that plasmid DNA was introduced into COS-7 cells by electro- 
potation (51).  Ohgo  dT- and random hexamer-primed cDNA 
libraries were mixed 1:1 and 20 I.tg of plasmid DNA was trans- 
fected into 4  ￿  107 COS-7 cells. After 60 h of culture, cells ex- 
pressing Ag 131/315 were immunologically selected using mAbs 
131  and 315.  Plasmid DNA was recovered as Hirt supematants 
and transformed into DH5el competent cells by electroporation. 
After four cycles of transfection and immunologic enrichment, 
plasmid DNA was prepared from single colonies and transfected 
into  COS-7  cells  by  the  DEAE-dextran  method.  Transfected 
cells were examined for expression of Ag 131/315  by flow cy- 
tometry using a FACScan  | 
Nudeotide Sequencing and Homology Search.  The insert DNA was 
subcloned into pBluescript  |  II SK+ phagemid vector (Stratagene 
Inc., La Jolla, CA). Nucleotide sequences were obtained by the 
dyedeoxy termination method using Taq DyeDeoxy Terminator 
Cycle Sequencing on a model 373A automated sequencer (Ap- 
plied Biosystems, Inc., Foster City, CA). Homology search was 
done  using Genetyx Mac/CD  ver.  29  (Software Development 
Co., Ltd., Tokyo, Japan). 
Production of&able Transfectants.  cDNAs were subcloned into 
an expression vector pMKITneo (kindly provided by Dr. K. Maru- 
yama) and transfected into Kit 225 cells or MMCE cells by electro- 
poration.  The  expression  vector  for  human  gp34,  pMKIT- 
neohgp34,  was constructed as follows. The  coding sequence  of 
human gp34 was amplified by reverse transcription-PCR ampli- 
fication of nucleotides 23-617 of human gp34 cDNA using total 
RNA  extracted from  MT-2  cells,  and  the  primers  5'-CCCA- 
GATTGTGAAGATGGAA  and 5'-GCCTGGTTTTAGATATT- 
GCC  (55). The PCR product was inserted into pT7Blue vector 
(Invitrogen). This  pT7hgp34  vector was  digested with BamHI 
and XbaI, and "~e resulting cDNA fragment was subcloned into 
the  BamHI/XbaI  site of pBluescript  |  SK+,  generating pBlue- 
script-hgp34, pMKITneohgp34 was constructed by transferring a 
XhoI/NotI  fragment  of pBluescript-hgp34  within  pMKITneo 
vector in  the  sense  orientation.  Cells were  centrifuged,  resus- 
pended in medium with 1 mg/ml Geneticin (GIBCO BILL), and 
dispensed 200  Ixl/well in 96-well plates. After 12-14 d, cultures 
were transferred to 24-well plates. Cells of each well were tested 
for expression of the relevant antigen by flow cytometry using a 
FACScan  | 
Results 
Generation  of mAbs that Inhibit Binding of ATL-43T  Cells 
to HUVECs.  During  the  screening  of HTLV-I-infected 
T  cell lines for the unknown pathway(s) of adhesion, it was 
incidentally noticed  that  ATL-43T  cells  showed  marked 
adhesion to HUVECs which was not inhibited by addition 
of any of the mAbs against LFA-1, VLA-4,  or E-selectin. 
After a long-tem~ in vitro culture, ATL-43T cells gradually 
lost  binding  activity  to  HUVECs  in  comparison  with 
freshly thawed original ATL-43T cells. Therefore, we im- 
munized  BALB/c  mice  with  original ATL-43T  cells and 
screened hybridomas based on  the  quantitative  difference 
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Figure 1.  Effects  of 13l as well as 315 hybridoma culture supematants 
on binding of ATL-43T  cells to HUVECs.  The binding of ATL-43T 
cells to HUVECs was inhibited by hybridoma culture supematants 131 as 
well as 315. S~Cr-labeled  ATL-43T cells were preincubated with medium 
alone, 10 I~g/ml W6/32 mAb (anvi-MHC class  1), or 1:1 dilutions ofhy- 
bridoma culture supematants for 10 rnin and then  added to HUVECs 
precultured in 96-well fiat-bottomed plates. The percentage of the re- 
maining adherent cells to the total input cells was calculated as described 
in Materials  and Methods. 
in reactivity between original and long-term--cultured ATL- 
43T cells. Then we checked the effects of the supernatants 
of the selected hybridomas on binding of ATL-43T cells to 
HUVECs. mAbs 131 and 315 were found to exhibit signif- 
icant inhibitory effects on cell adhesion between ATL-43T 
and HUVECs (Fig. 1). mAbs 131  and 315 were subtyped to 
be IgG1 and IgG2a, respectively. Immunoblotting and panel 
study of reactivity of these two mAbs clearly indicated that 
they recognize the same molecule as shown below. 
Expression  of Ag  131/315  on  PBMC  and  Various Cell 
Lines.  First we examined the expression of the Ags recog- 
nized by  mAbs  131  and  315  on  PBMC  and  various  cell 
hues  (Table  1).  Neither  131  nor 315  reacted with normal 
fresh PBMC.  However, as shown in Fig. 2,  after stimula- 
tion with P HA, expression of Ag 131/315 was detected on 
day  1,  reached maximal levels on  days 2-3,  and then  de- 
chned.  Two-color immunofluorescence  analyses revealed 
that  the  major  population  expressing Ag  131/315  is  the 
CD4 +  subset  of PHA-stimulated PBMC,  although  some 
CD8 + T  cells weakly expressed this Ag (data not shown). 
Among  the  cell lines  we  tested,  ATL-43T,  Hutl02,  and 
MT-2, which are all HTLV-I-infected human T  cell lines, 
were  found  to  be  positive for  this Ag.  Other  T,  B,  my- 
elomonocytoid, and (one) squamous cell lines were all neg- 
ative. These data suggest that Ag 131/315  expression is re- 
stricted  to  activated  T  cells  and  may  be  induced  in 
association with HTLV-I infection. 
Biochemical Characterization of  Ag 131/315.  Western  blot- 
ting was done to estimate the apparent molecular weight of 
the molecule recognized by mAbs 131  and 315.  Consistent 
with the data of flow cytometry, a unique 50-kD band was 
detected in Hutl02, ATL-43T, and PHA-stimulated PBMC 
by mAb 315  but not in Kit 225  or fresh PBMC  (Fig. 3). 
Western blotting with mAb 131  gave a band of the same mo- 
lecular weight (data not shown). Immunoprecipitation from 
day 3 PHA blasts by mAb 315 also showed a specific 50-kD 
band;  after digestion with  peptide N-glycosidase F  (New 
England Biolabs, Beverly, MA), the immunoprecipitates mi- 
grated at the apparent molecular mass of r  kD, indicat- 
ing that Ag 131/315  is a glycoprotein containing N-linked 
carbohydrate (data not shown). 
ATL-43T  T  +*  + 
Hut 102  T  +  + 
MT-1  T  -  - 
MT-2  T  +  + 
Kit 225  T  -  - 
MOLT-4  T  -  - 
HPB-ALL  T  -  - 
Jurkat  T  -  - 
HSB-2  T  -  - 
JY  B  -  - 
Daudi  B  -  - 
Raft  B  -  - 
HeLa  Epithelial  -  - 
HL60  Myeloid  -  - 
U937  Monocytoid  -  - 
HUVEC  Endothelial  -  - 
Normal PBMC (n =  5) 
Fresh  --  -- 
PHA-stimulated (3 d)  +  + 
*The cell surface expression of Ags 131 and 315 was examined by im- 
munofluorescence  staining and flow cytometry.  The cutoff range was 
set in the fluorescence histogram of staining with control  IgG at the 
right edge of the peak; percent positive cells  was then determined with 
mAb 131 or 315. (-): positive cells <10%,  (+): positive cells >10%. 
Isolation and Identification of cDNA  Encoding Ag  131/315. 
Since it seemed likely that mAbs 131  and 315 recognize an 
undefined adhesion molecule, we decided to isolate a cDNA 
clone encoding the Ag molecule by the expression cloning in 
COS-7 cells. After four cycles oftransfection and immuno- 
logic enrichment, individual plasmid clones were transfected 
by the DEAE-dextran method into COS-7 cells, and after 
48  h  of culture,  the expression of Ag 131/315  was  exam- 
ined by flow cytometry. One of the clones, pME18S315-02, 
containing a  1.1-kb insert, was  found to  encode the anti- 
genic epitope recognized by both mAbs 131  and 315 (Fig. 4). 
The  nucleotide  sequence  of the  insert  DNA  was  deter- 
mined using an automated sequencer and the sequence was 
subjected to the homology search.  To  our surprise, it was 
identical to  the  cDNA  of the  human  counterpart  of rat 
OX40  (data not shown).  The  cDNA we cloned included 
the sequence from the 5' end to a halfway point before the 
poly(A)  tail of the  published  human  OX40  cDNA.  It  is 
likely to encode the integral peptide as reported, which is 
supported by the fact that Western blotting of stable trans- 
fectants of our cDNA gave a band with the same molecular 
weight as PHA-stimulated normal PBMC  (data not shown). 
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Figure 2. 
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Expression of  Ag 315 on PBMC after stimulation with PHA. Normal PBMC were cultured with 0.1 Is.g/nil PHA, and the expression of  Ag 
315 (solid line) at the indicated time points was measured by indirect immunofluorescence  followed by flow cytometric analysis. Control indicates staining 
with irrelevant mouse IgG2a antibody (dotted line). 
Anti-OX40 mAbs Inhibit Binding of CD4 +-activated T  Cells 
to Vascular  Endothelial Cells.  As mentioned before, OX40 was 
identified  as an activation Ag predominantly  expressed  on 
the  CD4 +  population  of activated  T  cells  (40).  To  clarify 
whether OX40 can function as a cell adhesion molecule for 
activated  T  cells,  we performed  the  inhibition  study with 
mAb 315 using CD4 +  cells purified from PHA-stimulated 
PBMC. We first confirmed that the CD4 + PHA blasts ex- 
pressed  high  levels  of OX40  in  flow  cytometric  analysis 
(data  not shown).  The  cells were then  analyzed for adhe- 
sion activity to both resting and IL-l-stimulated HUVECs 
in  the  presence  or  absence  of mAbs.  Three  independent 
experiments  were  done with  samples  from three  different 
healthy volunteers, and a representative experiment is shown 
in Fig. 5. A considerable proportion of the cells were bound 
to unstimulated HUVECs. It was noted that 315 (anti-OX40 
mAb) rather than TS1/18  (anti-LFA-1 mAb) inhibited this 
adhesion and the addition of  both 315 and TS1/18 blocked 
most of the binding. When IL-l-stimulated HUVECs were 
used,  315,  TS1/18,  HP2/1  (anti-VLA-4  mAb),  and  7A9 
(anti-E-selectin  mAb)  each showed significant but modest 
inhibition by itself.  Combination of these mAbs clearly in- 
creased inhibitory effects on adhesion, and yet the effect of 
mAb  315  was  prominent  when  added  together  with  the 
other  mAbs.  Therefore,  the  cell  adhesion  to  IL-l-stimu- 
lated HUVECs seems to be mediated by the several pairs of 
adhesion molecules and a significant part of this adhesion is 
ascribed to OX40-mediated binding.  These data indicated 
that OX40 is involved in binding of activated CD4 + T  cells 
to  HUVECs,  whether  or not  HUVECs were  stimulated. 
As  to  other  types  of vascular  endothelial  cells,  binding  of 
CD4 §  PHA blasts to HAECs or HDMECs and its inhibi- 
tion by mAb 315 was similarly observed (data not shown). 
The Ligand for  OX40 on  Vascular Endothelial  Cells  is gp34. 
Recent studies have demonstrated that the ligand of OX40 
is gp34, a type II transmembrane protein of  the TNF family 
that is expressed on some HTLV-I-infected T  and activated 
B  cells  (42, 43).  Therefore, we next examined if gp34 was 
expressed  on HUVECs and  other types  of vascular endo- 
thelial  cells.  HUVECs,  HAECs, and HDMECs were stained 
with  anti-gp34  mAb and  analyzed by flow  cytometry. As 
2189  Imura et al. 
shown in Fig.  6, not only HUVECs but also HAECs and 
HDMECs  expressed  considerable  levels  of gp34  without 
any stimulation.  In fact,  no induction  or augmentation  of 
gp34  expression  was detected  after  culture  of these  endo- 
thelial  cells with  IL-113 (data  not shown).  Western  blot- 
ting was done  to characterize  the molecules expressed  on 
HUVECs that were recognized by 8F4, an anti-gp34 mAb. 
A  specific 34-kD  band  was  seen  by  8F4  in  HUVECs  and 
MT-2, indicating that HUVECs express the gp34 molecule 
of the  same  molecular  weight  as  originally  described  in 
HTLV-I-infected  T  cells  (Fig.  7).  We  then  examined  if 
anti-gp34 Ab could inhibit cell adhesion.  As had been ex- 
pected, 5A8, an anti-gp34 mAb, inhibited binding of ATL- 
Figure 3.  Western  blotting of Ag 315. Cell lysates of Kit 225, Hut102, 
ATL-43T, fresh PBMC, and PHA-stimnlated PBMC (day 3) were mixed 
with SDS-sample buffer, boiled for 5 rain, and then applied to electro- 
phoresis through a 7.5% polyacrylamide  gel. Proteins were transferred to a 
sheet of  PVDF membrane and the membrane was incubated  with 10 Ixg/ml 
mAb 315. The binding of  the mAb was detected as described in Materials 
and Methods. CD23  cDNA 
Control  H107  131  315 
1o ...................  lo  1;21;3'14  ~o  ~  1  lo 2  lo 3  lo 4  ,o ~  ~o ~  lo} ......  lo31o4  .......................  ~1;21;3  lo~ 
pME18S315-02 
lo 2''';63'''i84  18o..,;.81,.,,;.6e...;-6s.h-8  4 
1  ...... i  ...... i  ...... i  ..... 
100  101  102  10 3  104 
Figure 4.  Expression of Ags 131 and 315 on COS-7 cells transfected with the isolated cDNA clone. The isolated cDNA, pME18S315-02, as well as 
CD23 cDNA (Control) was transfected into COS-7 cells by the DEAE-dextran  method.  After 2 d of culture, cells were detached by 0.5 mM EDTA, 
stained with 10 p,g/ml H107 (anti-CD23 mAb), 131, or 315 by indirect immunofluorescence, and subjected to flow cytometric analysis. Control indi- 
cates staining the second antibody alone. 
43T  to  HUVECs  in  a  dose-dependent  manner  (Fig.  8). 
The  inhibition by mAb  5A8 was  even slightly more  effi- 
cient than that by mAb 315. These data clearly indicate that 
gp34 is the major OX40 ligand expressed on HUVECs. 
The  OX40/gp34  System  Directly Mediates  Cell Adhesion. 
Since both OX40 and gp34 have been reported to transmit 
stimulatory signals to the cell (42, 43), it is important to de- 
termine if the  OX40/gp34  system mediates  cell adhesion 
directly  or  indirectly by  activating other  adhesion  mole- 
cules.  To  address  this  question,  we  made  a  stable  OX40 
transfectant  of Kit  225  and  a  stable  gp34  transfectant  of 
MMCE,  a  mouse epithelial cell line  (Fig.  9).  Kit 225  ex- 
hibits almost no adhesion to MMCE  presumably due to the 
difference  in  species.  As  shown  in  Fig.  10,  OX40-trans- 
fected  Kit 225  cells that  did not bind to  parental MMCE 
cells showed marked adhesion to gp34-transfected MMCE 
cells,  whereas  no  binding between  parental  Kit  225  cells 
and the gp34 transfectants were  observed.  To further con- 
firm the role of the OX40/gp34  system in cell adhesion, a 
cell adhesion assay was done using paraformaldehyde-fixed 
cells  (Fig.  11).  Although  fixation  of either  ATL-43T  or 
HUVECs  decreased  the  binding capacity,  there  remained 
some  specific  binding  that  was  blocked  by  either  anti- 
OX40  or  anti-gp34 mAb.  These  results  strongly indicate 
that the  OX40/gp34  system directly mediates binding be- 
tween OX40 + T  cells and gp34 + vascular endothelial cells. 
Discussion 
OX40  was first identified on activated rat CD4 +  T  cells 
(40).  During the  past  several  years,  cDNAs  encoding rat, 
mouse, and human OX40 have been cloned (41, 56, 57).  It 
%  Adhesion 
HUVEC  Blocking mAbs  Used  20  40  60  80  Ill() 
i  i  i  i  t 
W6/32 
TSI/18  t 
unstimulated  3IS 
TSI/18 + 315  /  Figure  5.  Effects of anti-LFA-1, 
........................................  "@6"JA'2  ................................................................................................................................  i ........  anti-VLA-4,  anti-E-selectin,  and 
IL- l-stimulated 
TSI/18 
315 
111'211 
"1'S1/18  +  315 
315  +  11122/I 
TSI/18  +  1|132/I 
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TSI/18  +  7A9 
315  +  7A9 
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TSI/18  +  315  +  7A9 
315  +  IlP2lt  +  7A9 
1"51/18  +  HP2/I  +  7A9 
"rsl/18  +  315  +  HP2/I  +  7A9  m 
anti-OX40 mAbs on  the  binding 
of CD4 + PHA-stimulated PBMC 
to  HUVECs.  Purified  CD4  +  cells 
from PHA-stimulated PBMC (day 3) 
were preincubated with 10 Dg/ml of 
W6/32  (anti-MHC  class I  mAb), 
TS1/18  (anti-CD18  mAb),  315 
(anti-OX40 mAb), or HP2/1  (anti- 
VLA-4  mAb).  HUVECs were  also 
preincubated with 10 btg/ml of 7A9 
(anti-E-selectin mAb). The binding 
to  unstimulated  or  IL-l-stimulated 
HUVECs  was  then  detemfined  as 
described in Materials and Methods. 
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Figure 6.  Expression  of gp34 on 
vascular endothelial cells. HUVECs 
(A), HAECs (B), and HDMECs (C) 
cultured in vitro were stained with 
5A8  (anti-gp34 mAb) by  indirect 
immunofluorescence  and  subjected 
to flow cytometric analysis. (Dotted 
lines)  Staining with  control  mouse 
IgG2a antibody. 
has been shown that OX40 is a member of the TNF/NGF 
receptor family, which  also includes CD40,  Fas  (APO-1), 
CD30,  CD27,  and 4-1BB/ILA  (58-60).  The  members  of 
this family are type I  membrane molecules and contain in 
their extracellular domain three to four imperfect repeats of 
~40  residues, anchored by a  superimposable pattern of six 
cysteines. Expression of OX40  is restricted to  activated T 
cells, and the binding of OX40 to its ligand, gp34, has been 
reported  to  result  in  increased T  cell proliferation in  the 
presence  of suboptimal doses  of mitogens  (42,  43).  Thus, 
OX40  has been assumed to be a kind of cytokine receptor 
with  costimulatory  function  whose  ligand  is  membrane 
bound (42, 43, 61). 
In the present study, we  developed mAbs  131  and  315 
that inhibit adhesion between ATL-43T,  an ATL-derived 
T  cell line, and HUVECs.  Characterization of the Ag mol- 
ecule and subsequent cDNA cloning revealed that the 50-kD 
glycoprotein recognized by these mAbs is identical to  hu- 
man  OX40.  It was  unexpected  that  OX40,  a  member of 
the  NGF/TNF  receptor family, is involved in binding of 
ATL-43T  cells  to  HUVECs.  We  have  shown  that  the 
binding of CD4 +  PHA-stimulated PBMC  to  HUVECs  is 
also  inhibited  by  anti-OX40  mAbs.  In  particular,  their 
binding to unstimulated HUVECs is practically blocked by 
one of the anti-OX40 mAbs alone. 
gp34,  the ligand of OX40,  was previously described as a 
surface molecule expressed on certain HTLV-I-infected T 
cell fines  (44-46).  Although  it is known  that  gp34  is  ex- 
pressed in  multiple  organs  such  as  heart,  skeletal muscle, 
testis, and activated B  cells (42), expression ofgp34 in vail- 
Figure 7.  Western blotting ofgp34 expressed  in HUVECs. Cell lysates 
ofHUVECs, MT-2 cells, or Raft cells were subjected to SDS-PAGE and 
transferred to a sheet of PVDF membrane. The membrane was incubated 
with 10 p~g/ml  8F4 (anti-gp34 mAb) or negative control mAb. The bind- 
ing ofmAb was detected as described in Materials and Methods. 
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Figure 8.  Effects  ofanti-OX40 as well as anti-gp34 mAb on binding of 
ATL-43T cells to HUVECs. ATL-43T cells were preincubated with se- 
rial dilutions ofW6/32 (anti-MHC class  Im), 315 (anti-OX40 mAb A), 
or 5A8  (anti-gp34 mAb Q)  and then  subjected to the  adhesion assay. 
% Adhesion was formulated as a percentage of the binding with mAb to 
that without mAb. 
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Figure 9.  Expression  of OX40 and gp34 on the stable transfectants. Kit 
225 (A), a subline of Kit 225 stably transfected with pMKITneo contain- 
ing OX40 cDNA (B), MMCE (C), and MMCE stably transfected with 
pMKITneo containing gp34 cDNA (D)  were stained with 315  (anti- 
OX40 mAb) or 5A8 (anti-gp34 mAb) by indirect immunofluorescence 
and subjected to flow cytometric analysis. (Dotted lines) Staining with con- 
trol mouse IgG2a antibody. 
ous tissues and cell types has not been investigated in detail. 
Here we report for the  first time that human vascular en- 
dothelial cells including HUVECs, HAECs, and HDMECs, 
express  gp34  without  stimulation  in  vitro.  Furthermore, 
we  showed that  not  only anti-OX40  mAb but  also  anti- 
gp34 mAb inhibited binding of ATL-43T to HUVECs, in- 
dicating that the OX40/gp34 system participates in cell ad- 
hesion. 
As to  the  mechanism of cell  adhesion  mediated  by the 
OX40/gp34  system,  the  following  possibility  should  be 
taken into consideration. OX40/gp34 interaction may gen- 
erate  stimulatory signals resulting in increased binding ac- 
tivity of the other existing adhesion molecules. Indeed, Hol- 
lenbaugh  et  al.  (62)  have  reported  that  the  interaction  of 
CD40 expressed on vascular endothelial cells with its ligand 
can lead to endothelial  cell activation,  which in turn leads 
to leukocyte adhesion through the upregulation of ICAM-1, 
VCAM-1,  or E-selectin.  A  similar  explanation  also  seems 
possible  with  the  OX40/gp34  system.  Nevertheless,  it  is 
rather unlikely that the major part of cell adhesion shown in 
this study is indirectly mediated by stimulatory signals through 
the OX40/gp34 system. First,  incubation time in adhesion 
assay is too short to cause a quantitative  change in expres- 
sion  of other  adhesion  molecules.  Second,  cell  adhesion 
mediated  by  OX40  and  gp34  could  be  reconstructed  in 
OX40-transfected Kit 225 and gp34-transfected MMCE,  a 
mouse epithelial cell line lacking human ICAM-1, VCAM-1, 
and E-selectin.  This  adhesion was specifically inhibited  by 
anti-OX40  or anti-gp34 mAb.  Finally,  paraformaldehyde- 
fixed  ATL-43T  cells  still  showed  modest  but  significant 
binding to nonfixed or fixed HUVECs,  which was inhib- 
ited by anti-OX40 as well as anti-gp34 mAb. 
It is now realized that cell adhesion is a multistep process 
involving ligand receptor recognition  and subsequent  cel- 
lular activation. Most of the adhesion molecules themselves 
have  recently  been  shown  to  transmit  activation  signals 
(29-31).  A  number  of cytokines and  costimulatory mole- 
cules are also involved in this process by upregulating ex- 
pression  or  bindability  of adhesion  molecules.  However, 
there  is  another  aspect  of the  ligand  receptor  interaction: 
the  intercellular  binding between  membrane  molecules  is 
always  accompanied by physical  cell-to-cell  binding.  Ac- 
cordingly, it is rather natural  to presume that binding of a 
membrane-bound  molecule  to its  ligand  or receptor  con- 
tributes to cell-to-cell binding to some extent,  whether or 
not this contribution can be detected, depending on the as- 
say  system  and  coexistence  of other  adhesion  molecules. 
Our study presents such an interesting case in which a cy- 
tokine receptor-like molecule, OX40, and its ligand, gp34, 
can directly mediate cell adhesion. Remodeling of the con- 
cepts  of adhesion  and  costimulatory molecules will be re- 
quired to reconcile these results. 
T  cell  recruitment  has  been  investigated  based  on  the 
Cells 
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MMCE/gp34 - 
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Figure  10.  P,  econstitution of  the bind- 
ing mediated by OX40 and gp34 in the 
stable transfectants. Binding of  Kit 225 or 
its stable transfectants of OX40 (Kit225~ 
OX40) to MMCE or its stable transfec- 
tants of gp34 (MMCE/gp34)  was mea- 
sured in the presence or absence ofmAbs. 
Kit 225 or Kit 225/OX40 cells were pre- 
incubated with medium alone, W6/32 
(anti-MHC  class  I  mAb), 315  (anti- 
OX40 mAb), or 5A8 (anti-gp34 mAb), 
and subjected to the adhesion assay. 
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Figure  11.  Adhesion between  ATL- 
43T  and  HUVECs  after fixation with 
paraformaldehyde. ATL-43T  cells, un- 
fixed or fixed with 0.4% paraformalde- 
hyde for 10 rain at room temperature, 
were  preincubated  with  10  ~g/rnl  of 
W6/32  (anti-MHC  class I  mAb),  315 
(anti-OX40  mAb),  or 5A8  (anti-gp34 
mAb) and then  their binding  to HU- 
VECs,  unfixed  or  fixed  with  0.4% 
paraformaldehyde,  was measured. 
hypothesis that several pairs of homing receptors and vascu- 
lar addressins mediate adhesion of lymphoid cells to endo- 
thehal cells and regulate their localization. Therefore, tissue 
specificity of the homing of T  cell subsets is thought to be 
determined predominantly by cell type- or tissue-specific 
expression of a certain set of adhesion molecules including 
integrins,  Ig superfamily,  and  selectins.  The  OX40/gp34 
system seems to define a distinct pathway of T  cell recruit- 
ment  that  is  independent  of the  tissue  specificity or  the 
conditions of tissue environment, affecting any type of acti- 
vated CD4 + T  cells. It may be complementary to the con- 
ventional  tissue-specific cell  adhesion,  especially in  situa- 
tions where  a  significant proportion of circulating T  cells 
are activated and express OX40. 
Finally, the present study reemphasizes the importance of 
vascular endothelial cells for distribution and activation of 
T  cells. It is very hkely that interaction between T  cells and 
vascular endothehal cells via OX40  and gp34 generates ac- 
tivation signals to both sides in addition to the physical cell 
adhesion. Further studies are required to delineate its phys- 
iologic as well as pathologic meanings and the roles of vas- 
cular endothelial cells during this interaction for the better 
understanding of immune response in vivo. 
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